Suppr超能文献

基于药代动力学的方法鉴定源自甘草(甘草)根的拟醛固酮化合物,在服用连花清瘟胶囊后。

Pharmacokinetics-based identification of pseudoaldosterogenic compounds originating from Glycyrrhiza uralensis roots (Gancao) after dosing LianhuaQingwen capsule.

机构信息

Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.

出版信息

Acta Pharmacol Sin. 2021 Dec;42(12):2155-2172. doi: 10.1038/s41401-021-00651-2. Epub 2021 Apr 30.

Abstract

LianhuaQingwen capsule, prepared from an herbal combination, is officially recommended as treatment for COVID-19 in China. Of the serial pharmacokinetic investigations we designed to facilitate identifying LianhuaQingwen compounds that are likely to be therapeutically important, the current investigation focused on the component Glycyrrhiza uralensis roots (Gancao). Besides its function in COVID-19 treatment, Gancao is able to induce pseudoaldosteronism by inhibiting renal 11β-HSD2. Systemic and colon-luminal exposure to Gancao compounds were characterized in volunteers receiving LianhuaQingwen and by in vitro metabolism studies. Access of Gancao compounds to 11β-HSD2 was characterized using human/rat, in vitro transport, and plasma protein binding studies, while 11β-HSD2 inhibition was assessed using human kidney microsomes. LianhuaQingwen contained a total of 41 Gancao constituents (0.01-8.56 μmol/day). Although glycyrrhizin (1), licorice saponin G2 (2), and liquiritin/liquiritin apioside (21/22) were the major Gancao constituents in LianhuaQingwen, their poor intestinal absorption and access to colonic microbiota resulted in significant levels of their respective deglycosylated metabolites glycyrrhetic acid (8), 24-hydroxyglycyrrhetic acid (M2; a new Gancao metabolite), and liquiritigenin (27) in human plasma and feces after dosing. These circulating metabolites were glucuronized/sulfated in the liver and then excreted into bile. Hepatic oxidation of 8 also yielded M2. Circulating 8 and M2, having good membrane permeability, could access (via passive tubular reabsorption) and inhibit renal 11β-HSD2. Collectively, 1 and 2 were metabolically activated to the pseudoaldosterogenic compounds 8 and M2. This investigation, together with such investigations of other components, has implications for precisely defining therapeutic benefit of LianhuaQingwen and conditions for its safe use.

摘要

连花清瘟胶囊是一种由草药组合制成的药物,在中国被正式推荐用于治疗 COVID-19。在我们设计的一系列药代动力学研究中,旨在确定可能具有治疗重要性的连花清瘟化合物,当前的研究集中在甘草根(甘草)成分上。除了在 COVID-19 治疗中的作用外,甘草还能通过抑制肾脏 11β-HSD2 来诱导假性醛固酮症。在接受连花清瘟的志愿者和体外代谢研究中,对甘草化合物的全身和结肠腔内暴露进行了表征。使用人/大鼠、体外转运和血浆蛋白结合研究来描述甘草化合物对 11β-HSD2 的可及性,同时使用人肾微粒体评估 11β-HSD2 抑制作用。连花清瘟中总共含有 41 种甘草成分(0.01-8.56μmol/天)。尽管甘草酸(1)、甘草皂甙 G2(2)和甘草苷/甘草苷芹糖苷(21/22)是连花清瘟中的主要甘草成分,但它们在肠道中的吸收不良和对结肠菌群的作用导致它们各自的去糖基化代谢物甘草酸(8)、24-羟基甘草酸(M2;一种新的甘草代谢物)和甘草素(27)在人血浆和粪便中达到显著水平。这些循环代谢物在肝脏中被葡萄糖醛酸化/硫酸化,然后排泄到胆汁中。8 的肝氧化也产生 M2。具有良好膜通透性的循环 8 和 M2 可以进入(通过被动管状重吸收)并抑制肾脏 11β-HSD2。1 和 2 共同代谢激活为假性醛固酮化合物 8 和 M2。这项研究与对其他成分的此类研究一起,对于精确确定连花清瘟的治疗益处和安全使用条件具有重要意义。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验